Literature DB >> 2492837

Increased tissue-plasminogen activator (t-PA) levels in patients under oral anticoagulant therapy.

J Grulich-Henn1, K Loechelt, W Speiser, G Müller-Berghaus.   

Abstract

The fibrinolytic system was investigated in 30 patients under oral anticoagulant therapy, and in 23 control patients not receiving oral anticoagulants. Patients under oral anticoagulant therapy had significantly higher tissue-plasminogen activator (t-PA) antigen levels than patients in the control group. Mean t-PA levels before venous occlusion were 18.4 ng/ml in the anticoagulated patients vs. 7.9 ng/ml in the control patients (p less than 0.001). After venous occlusion for 10 minutes, t-PA levels were 45.0 ng/ml in the anticoagulated patients and 24.2 ng/ml in the control patients (p less than 0.01). Plasminogen activator inhibitor (PAI) capacity was not significantly different in the two groups before venous occlusion (VO) but differed slightly (p less than 0.05) after VO. The net decrease in euglobulin lysis time (ELT) after venous occlusion (= ELT before VO - ELT after VO), indicating the relative potency of the fibrinolytic activity in blood, was also significantly higher in the anticoagulated patients (median 240 min vs. 125 min, p less than 0.001). These data indicate that oral anticoagulant therapy increases the fibrinolytic activity in blood, and thus may have an additional therapeutic effect in addition to anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492837     DOI: 10.1007/bf00320234

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  23 in total

1.  Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI).

Authors:  J Gram; C Kluft; J Jespersen
Journal:  Thromb Haemost       Date:  1987-10-28       Impact factor: 5.249

2.  Sandwich ELISA for t-PA antigen employing a monoclonal antibody.

Authors:  C Korninger; W Speiser; J Wojta; B R Binder
Journal:  Thromb Res       Date:  1986-02-15       Impact factor: 3.944

Review 3.  The pharmacodynamics of the oral anticoagulant drugs.

Authors:  R A O'Reilly
Journal:  Prog Hemost Thromb       Date:  1974

4.  Evaluation of hemoconcentration from hematocrit measurements.

Authors:  W Van Beaumont
Journal:  J Appl Physiol       Date:  1972-05       Impact factor: 3.531

5.  Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity.

Authors:  Y Sakata; S Curriden; D Lawrence; J H Griffin; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

6.  A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group.

Authors: 
Journal:  Lancet       Date:  1980-11-08       Impact factor: 79.321

7.  Questions and answers on prothrombin time standardisation in oral anticoagulant control.

Authors:  E A Loeliger; L Poller; M Samama; J M Thomson; A M Van den Besselaar; J Vermylen; M Verstraete
Journal:  Thromb Haemost       Date:  1985-08-30       Impact factor: 5.249

8.  A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction.

Authors:  J Gram; J Jespersen
Journal:  Thromb Haemost       Date:  1987-04-07       Impact factor: 5.249

9.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

Authors:  A Hamsten; B Wiman; U de Faire; M Blombäck
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

10.  Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium.

Authors:  V W van Hinsbergh; R M Bertina; A van Wijngaarden; N H van Tilburg; J J Emeis; F Haverkate
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.